Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of DSP-0378 in Rare and Refractory Epilepsy (BAFME)
jRCT2051250187Phase 1Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DSP-0378 in Benign adult familial myoclonic epilepsy (BAFME), sponsored by Sumitomo Pharma. Primary endpoints: Safety, Pharmacokinetics and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
DSP-0378
03
Conditions
Benign adult familial myoclonic epilepsy (BAFME)
Beyond the preview
Go deeper on jRCT2051250187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250187.